Distinguished in Papilledema

Dr. Mark L. Moster

Ophthalmology | Neurology
840 Walnut St Ste 930, 
Philadelphia, PA 
Distinguished in Papilledema
840 Walnut St Ste 930, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Moster is an Ophthalmologist and a Neurologist in Philadelphia, Pennsylvania. Dr. Moster is rated as a Distinguished provider by MediFind in the treatment of Papilledema. His top areas of expertise are Optic Nerve Atrophy, Leber Hereditary Optic Neuropathy (LHON), Papilledema, Temporal Arteritis, and Vitrectomy.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Papilledema.

Specialties
Ophthalmology
Neurology
Licenses
Psychiatry & Neurology in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

840 Walnut St Ste 930, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Genetic, Other
Study Phase: Phase 3
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Biological, Device
Study Phase: Phase 3
Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients
Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients
Enrollment Status: Completed
Publish Date: February 08, 2021
Intervention Type: Other
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
Enrollment Status: Terminated
Publish Date: October 12, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Enrollment Status: Completed
Publish Date: January 23, 2020
Intervention Type: Biological, Device
Study Phase: Phase 3
Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis
Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis
Enrollment Status: Completed
Publish Date: August 22, 2017
Intervention Type: Drug
Study Phase: Early Phase 1
View 6 Less Clinical Trials

43 Total Publications

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.
Journal: JAMA ophthalmology
Published: December 19, 2024
Similar Doctors
Elite in Papilledema
Dr. Grant T. Liu
Neurology
Elite in Papilledema
Dr. Grant T. Liu
Neurology

Penn Pituitary Center

3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
 (1.8 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Grant Liu is a Neurologist in Philadelphia, Pennsylvania. Dr. Liu is rated as an Elite provider by MediFind in the treatment of Papilledema. His top areas of expertise are Increased Intracranial Pressure, Papilledema, Pseudotumor Cerebri Syndrome, Thymectomy, and Cataract Removal. Dr. Liu is currently accepting new patients.

Elite in Papilledema
Dr. Madhura A. Tamhankar
Ophthalmology
Elite in Papilledema
Dr. Madhura A. Tamhankar
Ophthalmology

Scheie Eye Institute Penn Presbyterian

51 N. 39th Street, 
Philadelphia, PA 
 (2.2 miles away)
215-662-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Madhura Tamhankar is an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Tamhankar is rated as a Distinguished provider by MediFind in the treatment of Papilledema. Her top areas of expertise are Papilledema, Strabismus, Optic Neuritis, Graves Disease, and Thymectomy. Dr. Tamhankar is currently accepting new patients.

Distinguished in Papilledema
Dr. Robert C. Sergott
Ophthalmology
Distinguished in Papilledema
Dr. Robert C. Sergott
Ophthalmology

Wills Eye Ophthalmology Clinic, Inc

840 Walnut St, Suite 1230, 
Philadelphia, PA 
 (0.3 miles away)
215-928-3041
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Sergott is an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Sergott is rated as a Distinguished provider by MediFind in the treatment of Papilledema. His top areas of expertise are Optic Nerve Atrophy, Leber Hereditary Optic Neuropathy (LHON), Papilledema, and Optic Neuritis. Dr. Sergott is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moster's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 19 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile